A comparison of complement assay results between treatment-naïve patients and patients with ITP receiving treatment revealed a statistically significant decrease in the mean C4 level in the treatment-naïve group (Fig. 4). This evidence concerns the gene C4A and autoimmune thrombocytopenic purpura.